Inverse 1,2,3-Triazole-1-yl-ethyl Substituted Hydroxamates as Highly Potent Matrix Metalloproteinase Inhibitors: (Radio)synthesis, in Vitro and First in Vivo Evaluation
- 16 August 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (17) , 6858-6870
Abstract
Noninvasive imaging and quantification of matrix metalloproteinase (MMP) activity in vivo are of great (pre)clinical interest. This can potentially be realized by using radiolabeled MMP inhibitors (MMPIs) as positron emission tomography (PET) imaging agents. Triazole-substituted MMPIs, discovered by our group, are highly potent inhibitors of MMP-2, -8, -9, and -13. The triazole ring and its position contribute significantly to the potency of the MMP inhibitor. To evaluate structure–activity relationships (SARs) of the initially discovered triazole-substituted MMPIs, an additional CH2-group between the backbone of the molecule and the triazole core was inserted, and the triazole ring was “inversed” by switching the alkyne and azide groups. Similar to the original triazole-substituted hydroxamates, the inverse triazole MMPIs are excellent inhibitors with promising invivo properties. Pharmacokinetic properties and metabolic stability of an 18F-labeled candidate in mice were investigated.Keywords
This publication has 42 references indexed in Scilit:
- Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal diseaseJournal of Pharmacy and Bioallied Sciences, 2012
- Proteases involved in cartilage matrix degradation in osteoarthritisBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2012
- Roles of matrix metalloproteinases in cancer progression and their pharmacological targetingThe FEBS Journal, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Molecular Targets of Rheumatoid ArthritisInflammation & Allergy - Drug Targets, 2008
- Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple SclerosisCurrent Pharmaceutical Biotechnology, 2008
- Matrix metalloproteinases: roles in cancer and metastasisFrontiers in Bioscience-Landmark, 2006
- Matrix Metalloproteinases in Vascular Remodeling and AtherogenesisCirculation Research, 2002
- Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosisExpert Opinion on Investigational Drugs, 2000
- Design and Therapeutic Application of Matrix Metalloproteinase InhibitorsChemical Reviews, 1999